Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY: DGX )

132.82 -1.06 (-0.79%)
Streaming Delayed Price Updated: 3:54 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 694,384
Open 133.51
Bid (Size) 132.81 (2)
Ask (Size) 132.88 (3)
Prev. Close 133.88
Today's Range 132.65 - 134.25
52wk Range 120.40 - 158.34
Shares Outstanding 122,180,759
Dividend Yield 1.69%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Want Growing Passive Income? Consider Buying This Stock
This maker of diagnostics tests has delivered 13 years of dividend growth to shareholders. 
Via The Motley Fool
Post-Accident Workforce Drug Positivity For Marijuana Reached 25-Year High In 2022, Quest Diagnostics Drug Testing Index Analysis Finds
The percentage of employees in the general U.S. workforce testing positive for marijuana following an on-the-job accident increased to its highest level in 25 years in 2022, according to a new analysis... 
Via Benzinga

Performance

YTD
-14.73%
-14.73%
1 Month
-4.77%
-4.77%
3 Month
-4.00%
-4.00%
6 Month
-10.87%
-10.87%
1 Year
-5.81%
-5.81%

More News

Read More
Exact Sciences Serves Investors Exactly What They Wished For
Via MarketBeat
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May
Via Benzinga
The Latest Analyst Ratings for Quest Diagnostics
Via Benzinga
Will Chart Analysts Notice Bad Omen on Quest Diagnostics's Chart
Via Benzinga
Quest Diagnostics Q1 Earnings Surpass Expectations; COVID-19 Testing Revenues Slump 80%
Via Benzinga
Analyst Expectations for Quest Diagnostics's Future
Via Benzinga
Analyst Expectations for Quest Diagnostics's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023
Via Benzinga
UiPath is a Cheaper and More Profitable AI Stock
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
Via Benzinga
Quest Diagnostics Inc. (NYSE: DGX) Making Surprising Moves in Friday Session
Via Investor Brand Network
Is This Healthcare Stock a Buy for Dividend Growth Investors?
Via The Motley Fool
2 Dividend Stocks That Recently Boosted Their Payouts by More Than 7%
Via The Motley Fool
5 Analysts Have This to Say About Quest Diagnostics
Via Benzinga
Down 40% in 2022, Can Exact Sciences Recover in 2023?
Via The Motley Fool
Analyst Ratings for Quest Diagnostics
Via Benzinga
These 2 Defensive Plays Are Highlights Of CNBC's 'Final Trades'
Via Benzinga
Where Quest Diagnostics Stands With Analysts
Via Benzinga
Golden Cross Appears Before Quest Diagnostics Investors
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Via Benzinga
Quest Diagnostics To Plunge 16%? Here Are 5 Other Price Target Changes For Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.